Literature DB >> 9071997

Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.

A P Dei Tos1, C Doglioni, S Piccinin, R Maestro, T Mentzel, M Barbareschi, M Boiocchi, C D Fletcher.   

Abstract

Dedifferentiated liposarcoma represents a distinct subtype of liposarcoma and is characterized by the presence of abrupt transition from well-differentiated liposarcoma to high-grade pleomorphic sarcoma (mostly MFH-like). A key role for p53 in tumour progression of this subset of liposarcomas has been suggested on the basis of p53 immunopositivity. A series of 14 dedifferentiated liposarcomas has been investigated by analysing the p53 gene and protein together with the p53-related molecules p21Waf1 and mdm2, to verify whether the p53 pathway is involved in the development and progression of this tumour type. The results indicate that the p53 gene is rarely involved in dedifferentiated liposarcoma (7 per cent of cases analysed) and that low percentages of p53 immunopositivity are still compatible with integrity of the p53 gene. This concept is also supported by the observed preservation of p21Waf1 immunoreactivity in all but the p53-mutated cases. By contrast, mdm2 overexpression emerges as the most frequent abnormality in dedifferentiated liposarcoma (57 and 78 per cent of cases in well-differentiated and high-grade areas, respectively).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071997     DOI: 10.1002/(SICI)1096-9896(199701)181:1<8::AID-PATH700>3.0.CO;2-#

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Dedifferentiated liposarcoma with rhabdomyoblastic differentiation.

Authors:  Shio Shimada; Takashi Ishizawa; Keisuke Ishizawa; Kouichi Kamada; Takanori Hirose
Journal:  Virchows Arch       Date:  2005-07-13       Impact factor: 4.064

2.  Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma.

Authors:  A P Dei Tos; S Piccinin; C Doglioni; T Vukosavljevic; T Mentzel; M Boiocchi; C D Fletcher
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

3.  Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience.

Authors:  Ronald S A de Vreeze; Daphne de Jong; Petra M Nederlof; Aafke Ariaens; Ivon H G Tielen; Luc Frenken; Rick L Haas; Frits van Coevorden
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

4.  A case of dedifferentiated solitary fibrous tumor in the pelvis with TP53 mutation.

Authors:  Aiko Kurisaki-Arakawa; Keisuke Akaike; Kieko Hara; Atsushi Arakawa; Michiko Takahashi; Keiko Mitani; Takashi Yao; Tsuyoshi Saito
Journal:  Virchows Arch       Date:  2014-11       Impact factor: 4.064

5.  p14(ARF) methylation is a common event in the pathogenesis and progression of myxoid and pleomorphic liposarcoma.

Authors:  Radoslav Davidović; Jelena Sopta; Vesna Mandušić; Milena Krajnović; Maja Stanojević; Goran Tulić; Bogomir Dimitrijević
Journal:  Med Oncol       Date:  2013-08-06       Impact factor: 3.064

6.  Liposarcoma: molecular genetics and therapeutics.

Authors:  Rachel Conyers; Sophie Young; David M Thomas
Journal:  Sarcoma       Date:  2010-12-27

7.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09

8.  An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas.

Authors:  Nader Touqan; Christine P Diggle; Edlo T Verghese; Sarah Perry; Kieran Horgan; William Merchant; Rashida Anwar; Alexander F Markham; Ian M Carr; Rajgopal Achuthan
Journal:  BMC Clin Pathol       Date:  2013-12-13

9.  The marriage between pathology and genetics: are we ready for clinical use?

Authors:  Angelo P Dei Tos
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.